Contact Book a call
+33 (0)3 90 20 54 70
Contact Book a call
Contact Book a call
Nycodenz AG® Nycodenz AG® XtenCHO ™ Starter kit XtenCHO ™ Starter kit
View all Products

Human VEGF Recombinant Protein

Reference:
Size

100ug, 50ug
Brand

Product type

Host Species

Applications

,

Tags:
Specification
Documents
Publications
Reviews
Product nameHuman VEGF Recombinant Protein
Uniprot IDP15692
Uniprot linkhttp://www.uniprot.org/uniprot/P15692
Origin speciesHomo sapiens (Human)
Expression systemProkaryotic expression
SequenceMAHNHRHKHKLDDDDKAPMAEGGGQNHHEVVKFMDVYQRSYCHPIETLVDIFQEYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTEESNITMQIMRIKPHQGQHIGEMSFLQHNKCECRPKKDR
Molecular weight14,65 kDa
Protein delivered with Tag?Yes
Purity estimated70%
BufferPBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol
FormFrozen
Delivery conditionDry Ice
Delivery lead time in business days3-5 days if in stock; 3-5 weeks if production needed
Storage condition4°C for short term (1 week), -20°C or -80°C for long term (avoid freezing/thawing cycles; addition of 20-40% glycerol improves cryoprotection)
BrandProteoGenix
Host speciesEscherichia coli (E.coli)
ApplicationsELISA,WB
Fragment TypePartial
Protein AccessionAAH65522.2
Spec:Entrez GeneID7422
Spec:NCBI Gene AliasesMVCD1, VPF, VEGF
Spec:SwissProtIDP15692
NCBI ReferenceAAH65522.2
Aliases /SynonymsVEGF, VEGFA protein, Vascular endothelial Growth Factor proteins A, VEGF-A, Vascular permeability factor, VPF, VEGFA
ReferencePX-P1060
NoteFor research use only.
Datasheet Download

Publication

  • 1: Burmeister K, Quagliata L, Andreozzi M, Eppenberger-Castori S, Matter MS, Perrina V, Grobholz R, Jochum W, Horber D, Moosmann P, Lehmann F, Köberle D, Ng CK, Piscuoglio S, Tornillo L, Terracciano LM. Vascular endothelial Growth Factor proteins A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes. PLoS One. 2017 Apr 12;12(4):e0175563. doi: 10.1371/journal.pone.0175563. eCollection 2017. PubMed PMID: 28403223; PubMed Central PMCID: PMC5389821.
  • 2: Yin J, Shen L, Ji M, Wu Y, Cai S, Chen J, Yao Z, Ge J. Inverse Relationship between Serum VEGF Levels and Late In-Stent Restenosis of Drug-Eluting Stents. Biomed Res Int. 2017;2017:8730271. doi: 10.1155/2017/8730271. Epub 2017 Mar 8. PubMed PMID: 28373989; PubMed Central PMCID: PMC5360953.
  • 3: Ruffolo C, Toffolatti L, Canal F, Kotsafti A, Pagura G, Pozza A, Campo Dell'Orto M, Ferrara F, Massani M, Dei Tos AP, Castoro C, Bassi N, Scarpa M. Colorectal polypoid lesions and expression of vascular endothelial Growth Factor proteins in a consecutive series of endoscopic and surgical patients. Tumour Biol. 2017 Mar;39(3):1010428317692263. doi: 10.1177/1010428317692263. PubMed PMID: 28347226.
  • 4: Naykoo NA, Dil-Afroze, Rasool R, Shah S, Ahangar AG, Bhat IA, Qasim I, Siddiqi MA, Shah ZA. Single nucleotide polymorphisms, haplotype association and tumour expression of the vascular endothelial Growth Factor proteins (VEGF) gene with lung carcinoma. Gene. 2017 Apr 15;608:95-102. doi: 10.1016/j.gene.2017.01.007. Epub 2017 Jan 23. PubMed PMID: 28122267.
  • 5: Zhuo Y, Zeng Q, Zhang P, Li G, Xie Q, Cheng Y. VEGF Promoter Polymorphism Confers an Increased Risk of Pulmonary Arterial Hypertension in a Chinese Population. Yonsei Med J. 2017 Mar;58(2):305-311. doi: 10.3349/ymj.2017.58.2.305. PubMed PMID: 28120560; PubMed Central PMCID: PMC5290009.
  • 6: Dang YZ, Zhang Y, Li JP, Hu J, Li WW, Li P, Wei LC, Shi M. High VEGFR1/2 expression levels are predictors of poor survival in patients with cervical cancer. Medicine (Baltimore). 2017 Jan;96(1):e5772. doi: 10.1097/MD.0000000000005772. PubMed PMID: 28072723; PubMed Central PMCID: PMC5228683.
  • 7: Martynova EV, Valiullina AH, Gusev OA, Davidyuk YN, Garanina EE, Shakirova VG, Khaertynova I, Anokhin VA, Rizvanov AA, Khaiboullina SF. High Triglycerides Are Associated with Low Thrombocyte Counts and High VEGF in Nephropathia Epidemica. J Immunol Res. 2016;2016:8528270. doi: 10.1155/2016/8528270. Epub 2016 Dec 5. PubMed PMID: 28053993; PubMed Central PMCID: PMC5178363.
  • 8: López-Cancio E, Ricciardi AC, Sobrino T, Cortés J, de la Ossa NP, Millán M, Hernández-Pérez M, Gomis M, Dorado L, Muñoz-Narbona L, Campos F, Arenillas JF, Dávalos A. Reported Prestroke Physical Activity Is Associated with Vascular Endothelial Growth Factor proteins Expression and Good Outcomes after Stroke. J Stroke Cerebrovasc Dis. 2017 Feb;26(2):425-430. doi: 10.1016/j.jstrokecerebrovasdis.2016.10.004. Epub 2016 Oct 28. PubMed PMID: 28029607.
  • 9: Ghazizadeh H, Fazilati M, Pasdar A, Avan A, Tayefi M, Ghasemi F, Mehramiz M, Mirhafez SR, Ferns GA, Azimi-Nezhad M, Ghayour-Mobarhan M. Association of a Vascular Endothelial Growth Factor proteins genetic variant with Serum VEGF level in subjects with Metabolic Syndrome. Gene. 2017 Jan 20;598:27-31. doi: 10.1016/j.gene.2016.10.034. Epub 2016 Oct 27. PubMed PMID: 27984191.
  • 10: Barchitta M, Maugeri A. Association between Vascular Endothelial Growth Factor Polymorphisms and Age-Related Macular Degeneration: An Updated Meta-Analysis. Dis Markers. 2016;2016:8486406. doi: 10.1155/2016/8486406. Epub 2016 Nov 23. PubMed PMID: 27999450; PubMed Central PMCID: PMC5141552.
  • 11: Li J, Sun K, Chen Z, Shi J, Zhou D, Xie G. A fluorescence biosensor for VEGF detection based on DNA assembly structure switching and isothermal amplification. Biosens Bioelectron. 2017 Mar 15;89(Pt 2):964-969. doi: 10.1016/j.bios.2016.09.078. Epub 2016 Sep 30. PubMed PMID: 27816590.
  • 12: Rotar IC, Dumitras DE, Popp RA, Petrisor FM, Cotutiu P, Stamatian F, Muresan D. VEGF +936 C/T Genetic Polymorphism in Patients with Cervical Dysplasia. Anal Cell Pathol (Amst). 2016;2016:6074275. Epub 2016 Oct 12. PubMed PMID: 27812483; PubMed Central PMCID: PMC5080462.
  • 13: Hu ZQ, Xue H, Long JH, Wang Y, Jia Y, Qiu W, Zhou J, Wen ZY, Yao WJ, Zeng Z. Biophysical Properties and Motility of Human Mature Dendritic Cells Deteriorated by Vascular Endothelial Growth Factor proteins through Cytoskeleton Remodeling. Int J Mol Sci. 2016 Oct 31;17(11). pii: E1756. PubMed PMID: 27809226; PubMed Central PMCID: PMC5133777.
  • 14: Camerin GR, Brito AB, Vassallo J, Derchain SF, Lima CS. VEGF gene polymorphisms and outcome of epithelial ovarian cancer patients. Future Oncol. 2017 Feb;13(5):409-414. doi: 10.2217/fon-2016-0299. Epub 2016 Oct 26. PubMed PMID: 27780361.
  • 15: Lee S, Kang HG, Choi JE, Lee JH, Kang HJ, Baek SA, Lee E, Seok Y, Lee WK, Lee SY, Yoo SS, Lee J, Cha SI, Kim CH, Cho S, Park JY. The Different Effect of VEGF Polymorphisms on the Prognosis of Non-Small Cell Lung Cancer according to Tumor Histology. J Korean Med Sci. 2016 Nov;31(11):1735-1741. doi: 10.3346/jkms.2016.31.11.1735. PubMed PMID: 27709850; PubMed Central PMCID: PMC5056204.

Reviews

There are no reviews yet.

REVIEW YOUR PRODUCT

Be the first to review “Human VEGF Recombinant Protein”

Your email address will not be published. Required fields are marked *

Related products

Bevacizumab Biosimilar – Anti-VEGF mAb – Research Grade
Biosimilar

Bevacizumab Biosimilar – Anti-VEGF mAb – Research Grade

PX-TA1006 300€
View product
Ranibizumab Biosimilar – Anti-VEGF mAb – Research Grade
Biosimilar

Ranibizumab Biosimilar – Anti-VEGF mAb – Research Grade

PX-TA1008 400€
View product
Aflibercept Biosimilar – Anti-VEGF mAb – Research Grade
Biosimilar

Aflibercept Biosimilar – Anti-VEGF mAb – Research Grade

PX-TA1016 300€
View product
Ramucirumab Biosimilar – Anti-VEGFR-2 mAb – Research Grade
Biosimilar

Ramucirumab Biosimilar – Anti-VEGFR-2 mAb – Research Grade

PX-TA1023 300€
View product
IMC-1C11 Biosimilar – Anti-VEGFA mAb – Research Grade
Biosimilar

IMC-1C11 Biosimilar – Anti-VEGFA mAb – Research Grade

PX-TA1132 400€
View product
Alacizumab Biosimilar – Anti-KDR, VEGFR2, CD309 mAb – Research Grade
Biosimilar

Alacizumab Biosimilar – Anti-KDR, VEGFR2, CD309 mAb – Research Grade

PX-TA1167 400€
View product
Icrucumab Biosimilar – Anti-FLT1, VEGFR-1 mAb – Research Grade
Biosimilar

Icrucumab Biosimilar – Anti-FLT1, VEGFR-1 mAb – Research Grade

PX-TA1257 400€
View product
Vesencumab Biosimilar – Anti-Neuropilin-1, NRP1, VEGF165R extracellular domain mAb – Research Grade
Biosimilar

Vesencumab Biosimilar – Anti-Neuropilin-1, NRP1, VEGF165R extracellular domain mAb – Research Grade

PX-TA1266 400€
View product
Vanucizumab Biosimilar – Anti-ANGPT2, VEGFA, mAb – Research Grade
Biosimilar

Vanucizumab Biosimilar – Anti-ANGPT2, VEGFA, mAb – Research Grade

PX-TA1355 400€
View product
Brolucizumab Biosimilar – Anti-VEGFA mAb – Research Grade
Biosimilar

Brolucizumab Biosimilar – Anti-VEGFA mAb – Research Grade

PX-TA1374 400€
View product
Varisacumab Biosimilar – Anti-VEGFA mAb – Research Grade
Biosimilar

Varisacumab Biosimilar – Anti-VEGFA mAb – Research Grade

PX-TA1458 400€
View product
Faricimab Biosimilar – Anti-ANGPT2, VEGFA mAb – Research Grade
Biosimilar

Faricimab Biosimilar – Anti-ANGPT2, VEGFA mAb – Research Grade

PX-TA1501 400€
View product
Olinvacimab Biosimilar – Anti-KDR, VEGFR2 mAb – Research Grade
Biosimilar

Olinvacimab Biosimilar – Anti-KDR, VEGFR2 mAb – Research Grade

PX-TA1520 400€
View product
Dilpacimab Biosimilar – Anti-DLL4, VEGFA mAb – Research Grade
Biosimilar

Dilpacimab Biosimilar – Anti-DLL4, VEGFA mAb – Research Grade

PX-TA1525 400€
View product

Contact us

Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.






    Cart (0 Items)

    Your cart is currently empty.

    View Products